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Characterizing and prognosticating chronic
lymphocytic leukemia in the elderly:
prospective evaluation on 455 patients
treated in the United States
Chadi Nabhan1*, Anthony Mato2, Christopher R. Flowers3, David L. Grinblatt4, Nicole Lamanna5, Mark A. Weiss6,
Matthew S. Davids7, Arlene S. Swern8, Shriya Bhushan8, Kristen Sullivan9, E. Dawn Flick10, Pavel Kiselev8
and Jeff P. Sharman11

Abstract
Background: Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is > 70 years. However,
the majority of clinical trials do not reflect the demographics of CLL patients treated in the community. We examined
treatment patterns, outcomes, and disease-related mortality in patients ≥ 75 years with CLL (E-CLL) in a real-world setting.
Methods: The Connect® CLL registry is a multicenter, prospective observational cohort study, which enrolled 1494 adult
patients between 2010–2014, at 199 US sites. Patients with CLL were enrolled within 2 months of initiating first line of
therapy (LOT1) or a subsequent LOT (LOT ≥ 2). Kaplan–Meier methods were used to evaluate overall survival. CLL- and
infection-related mortality were assessed using cumulative incidence functions (CIF) and cause-specific hazards. Logistic
regression was used to develop a classification model.
Results: A total of 455 E-CLL patients were enrolled; 259 were enrolled in LOT1 and 196 in LOT ≥ 2. E-CLL patients were
more likely to receive rituximab monotherapy (19.3 vs. 8.6%; p < 0.0001) and chemotherapy-alone regimens (p < 0.0001)
than younger patients. Overall and complete responses were lower in E-CLL patients than younger patients when given
similar regimens. With a median follow-up of 3 years, CLL-related deaths were higher in E-CLL patients than
younger patients in LOT1 (12.6 vs. 5.1% p = 0.0005) and LOT ≥ 2 (31.3 vs. 21.5%; p = 0.0277). Infection-related
deaths were also higher in E-CLL patients than younger patients in LOT1 (7.4 vs. 2.7%; p = 0.0033) and in LOT ≥ 2 (16.2 vs.
11.2%; p = 0.0786). A prognostic score for E-CLL patients was developed: time from diagnosis to treatment < 3 months,
enrollment therapy other than bendamustine/rituximab, and anemia, identified patients at higher risk of inferior survival.
Furthermore, higher-risk patients experienced an increased risk of CLL- or infection-related death (30.6 vs 10.3%;
p = 0.0006).
Conclusion: CLL- and infection-related mortality are higher in CLL patients aged ≥ 75 years than younger patients,
underscoring the urgent need for alternative treatment strategies for these understudied patients.
Trial Registration: The Connect CLL registry was registered at clinicaltrials.gov: NCT01081015 on March 4, 2010.
Keywords: Chronic lymphocytic leukemia, Connect® CLL registry, Elderly, Prognostic, Chemoimmunotherapy
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Background
Chronic lymphocytic leukemia (CLL) accounts for
15 000 diagnosed cases in the USA annually [1]. While
incremental improvements in treating CLL have been
observed in the past decade [2], the majority of clinical
trials leading to these treatment approaches have largely
enrolled younger, fitter patients who do not accurately
reflect the demographics of CLL patients seen in the
community [3–6]. One exception was the CLL-11 study
that compared chlorambucil alone to chlorambucil
combined with rituximab or obinutuzumab in patients
with co-morbidities defined as either a glomerular-filtration
rate < 70 mL/min or a cumulative-illness-rating scale ≥ 6
[7]. Other studies have allowed enrollment of elderly
patients and performed unplanned subset analyses in an attempt to refine treatments and outcomes in the elderly, but
data were inconclusive [8–10]. Moreover, a populationbased analysis of 28 590 US patients diagnosed with CLL
(1992–2009) showed that the improvement in overall
survival (OS) noted in younger patients was less pronounced in the elderly [11]. Furthermore, Brenner et al.
[12] showed that improved survival for CLL has not
been observed in older patients.
Whether these differences are related to disparities in
therapeutic choice, access to care, non-CLL-related deaths
in elderly patients, or variations in CLL biology and prognostic indicators is unknown. As the median age of CLL
patients at diagnosis approaches 72 years, understanding
the biology and outcomes for elderly patients is critical
and underscored by the reported inferior survival of these
patients.
To examine treatment patterns and disease-related
outcomes in elderly CLL patients (defined as ≥ 75 years),
we used the Connect® CLL database that enrolled 1494
CLL patients requiring therapy between 2010 and 2014
[13]. These patients were almost entirely enrolled prior
to the introduction of novel B-cell receptor (BCR)-targeted therapies. We aimed to establish a benchmark for
outcomes in elderly CLL patients treated before the
availability of BCR-targeted therapies to help in properly
positioning newer agents in the elderly CLL treatment
paradigm. Our objective was to compare patient and
disease characteristics, prognostic indicators, complications, and disease-related mortality. Further, we aimed
to develop a prognostic score that predicts elderly CLL
patients at highest risk of CLL- or infection-related
deaths. To our knowledge, this represents the largest
comprehensive, prospective evaluation of this patient
population published to date.
Methods
Study design and participants

The Connect CLL registry (NCT01081015), a multicenter,
prospective, observational cohort study enrolled 1494 CLL
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patients treated at 199 US community- and academicbased sites from March 2010 to January 2014 [13]. The
study protocol was approved by a central institutional
review board (IRB) (Quorum Review IRB, Seattle, WA,
USA) or each site’s IRB (Additional file 1). Eligible patients
were ≥ 18 years and had CLL as defined by the International Workshop on Chronic Lymphocytic Leukemia
(IWCLL) guidelines [14]. Eligible patients were those
initiating a first or higher line of therapy (LOT) within
2 months prior to study enrollment. Personnel were educated to enroll patients consecutively as they entered
a LOT and to invite every eligible patient to participate
in the registry. For this analysis, patients were divided
into two groups based on LOT: first line of therapy
(LOT1) and second line of therapy or greater (LOT ≥ 2).
Each patient was followed up for up to 60 months or until
early discontinuation (i.e. due to death, withdrawal of consent, loss to follow-up, or study termination). Follow-up
data were collected approximately every 3 months during
study participation. Reasons for treatment initiation and
responses were assessed by the treating physician.
Statistical analysis

Date of enrollment was considered baseline for this study.
Only laboratory samples collected < 7 days before the start
of enrollment therapy were used for baseline laboratory
testing. Disease and patients’ characteristics, practice
patterns, clinical outcomes, and disease-related mortality
were assessed. Continuous variables were reported using
measures of dispersion and central tendency (means,
medians, ranges, and standard deviation [SD]); categorical
variables were reported as numbers and percentages
(proportionality, 95% confidence intervals [CI]) of the
total study population. Medical history at enrollment
and pre-existing condition data were used to generate a
Charlson Comorbidity Index (CCI) [15, 16]. Results
were summarized by LOT at enrollment (LOT1 or
LOT ≥ 2) and by age group (< 75 years and ≥ 75 years).
The Chi-square test for the comparison of rates was
used to assess differences between patient subgroups.
Statistical significance was assessed at p = 0.05 (two-sided).
The Breslow-Day test was used to assess the homogeneity
of the odds ratios.
The Kaplan–Meier method was used to estimate survival,
calculated from the date on which therapy was initiated
[17]. p value was derived from log-rank tests for comparison of survival distributions. CLL-related deaths due to
disease progression were distinguished from deaths due to
other causes and recorded by the treating physician. CLLor infection-related survival was assessed using cumulative
incidence functions (CIFs); p values from Gray’s test for
equality of CIFs were reported. Cause-specific hazards
analysis identified predictors of survival in univariate
and multivariable settings. Predictors demonstrating an
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association with time to event (p < 0.1) were included
in multivariable analyses to identify significant independent predictors. Cause-specific hazard ratios (HR)
and 95% CI were calculated.
Predictive modeling using logistic regression and a
k-fold cross-validation method with k = 5 was used to
develop a prognostic score for elderly CLL patients
[18]. Results were confirmed by assessment of the interaction between the above covariates and the elderly CLL
group in the analysis of all eligible patients. Statistical
analyses were performed using SAS® (version 9.2) statistical
software (SAS Institute, Cary, NC, USA).

Results
Patient characteristics

Table 1 shows that of 1494 patients enrolled in the registry,
455 patients were ≥ 75 years; 259 patients ≥ 75 years were
enrolled in LOT1 and 196 in LOT ≥ 2. Patient demographics and disease characteristics were largely similar between
patients enrolled in LOT1 and LOT ≥ 2, with the exception
of duration of CLL from diagnosis to enrollment (1.8 vs
7.2 years at LOT ≥ 2). Differences were also observed
between patients aged < 75 and ≥ 75 years for Rai staging,
constitutional symptoms, and ECOG score at LOT1, and
for sex, time from diagnosis to first LOT, race, geographical
region, and ECOG score at LOT ≥ 2 (Table 1).
Treatment patterns

Elderly CLL patients were more likely to receive rituximab
monotherapy than younger patients, regardless of LOT
(19.3 vs. 8.6% in LOT1; 15.3 vs. 12.7% in LOT ≥ 2). This
was significant for patients receiving LOT1 (p < 0.0001)
(Table 2). Patients ≥ 75 years in LOT ≥ 2 were significantly
less likely to receive bendamustine/rituximab (BR) than
patients < 75 years (21.9 vs. 30.6%; p = 0.0267). Only
6.9% of patients ≥ 75 years in LOT1 received fludarabine/cyclophosphamide/rituximab (FCR), versus 33.7%
of patients < 75 years (p < 0.0001). Interestingly, patients
≥ 75 years were significantly more likely to receive chemotherapy alone without anti-CD20 antibody therapy than
patients < 75 years. This was true for LOT1 (20.1 vs. 10.3%;
p < 0.0001) and LOT ≥ 2 (25.5 vs. 11.0%; p < 0.0001).
Geographic variations in treatment patterns were also
observed. In elderly CLL patients in LOT1, the South
had the highest utilization of rituximab-based regimens
(61.2%) while the West had the lowest (29.2%; p < 0.0023).
For patients covered by private insurance, younger CLL
patients were more likely to receive rituximab-based therapies than elderly CLL patients (80.1 vs. 50.0%; p < 0.0001).
This was also observed for patients covered by other
insurance providers including Medicare, Medicaid, and
military health insurance (71.8 vs. 54.5%; p < 0.0001). When
analyzed using the Breslow-Day test, the results did not
differ significantly by health insurance coverage (p = 0.0879).
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Response and survival

For all patients enrolled in LOT1, overall response rate
(ORR) was 60.2% (38.1% complete response [CR]) while
patients enrolled in LOT ≥ 2 had an ORR of 42.6%
(17.0% CR). In LOT1, ORRs were significantly lower in
patients ≥ 75 years compared with patients < 75 years
(ORR: 48.3 vs. 65.1% respectively; p < 0.0001 and CR:
25.9 vs. 42.3%, respectively; p < 0.0001). Lower ORR
and CR were also observed for elderly CLL patients in
LOT1 when specific enrollment therapies were analyzed
(Additional file 2: Table S1). Similarly, lower ORRs were
observed in LOT ≥ 2 (CR: 11.2 vs. 19.8%; p = 0.009). As
responses were investigator-assessed, we investigated
whether patients were evaluated by imaging at enrollment. Patients ≥ 75 years were less likely to be evaluated by imaging than patients < 75 years (65.4 vs. 72.0%;
p = 0.004). This finding was maintained after adjusting
for LOT.
Outcomes

As of August 25, 2015, with a median follow-up of
32.6 months for all 1494 patients, 433 (29%) had died;
causes of death are summarized in Fig. 1. As expected,
OS was significantly lower in patients ≥ 75 years than
patients < 75 years in both LOT1 (log-rank p < 0.0001;
Fig. 2a) and LOT ≥ 2 (log-rank p < 0.0001; Fig. 2b).
Notably, elderly CLL patients were more likely to die
from CLL in LOT1 (12.6 vs. 5.1%, Gray’s test p = 0.0005;
Fig. 3a) and LOT ≥ 2 (31.3 vs. 21.5%, Gray’s test p = 0.0277;
Fig. 3b). Time to death from CLL or infection in patients in
LOT1 was also significantly shorter in patients ≥
75 years than patients < 75 years (Gray’s test p <
0.0001; Fig. 3c), and in patients in LOT ≥ 2 (Gray’s test
p = 0.0014; Fig. 3d). Analysis of cause-specific hazards
was performed to identify predictors of death from
CLL in patients enrolled in LOT1. In univariate analyses, insurance status, anemia, del(17p) abnormality,
and age ≥ 75 years (Additional file 3: Table S2) were
identified as significant factors. Multivariable analysis
retained age ≥ 75 years at enrollment (HR: 3.66, 95%
CI 1.92–7.00), and the presence of the del(17p) abnormality (by fluorescence in situ hybridization or cytogenetic testing) (HR: 2.63, 95% CI 1.20–5.78) as
independent predictors of a higher risk of death.
Prognostic model for early death from CLL or infection in
elderly CLL patients

We performed prognostic modeling on 181 elderly CLL
patients receiving LOT1 who were followed up for ≥ 2 years.
Modeling was carried out using the k-fold cross-validation
method. Due to the limited sample size, a 5-fold crossvalidation approach was chosen. The sample of 181 patients
was randomly partitioned into five validation subsets of
approximately equal size. Five models were generated using
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Table 1 Demographics and characteristics of patients at enrollment to therapy
LOT ≥ 2 (n = 605)

LOT1 (n = 889)
< 75 years

≥ 75 years

(n = 630)
Mean
SD

< 75 years

≥ 75 years

(n = 259)

(n = 409)

(n = 196)

62.4

80.4

63.9

80.8

8.26

4.33

7.67

4.37

Median

63.0

80.0

65.0

80.0

Range

22–74

75–99

34–74

75–96

Male

411 (65.2)

155 (59.8)

281 (68.7)

106 (54.1)

Female

219 (34.8)

104 (40.2)

128 (31.3)

90 (45.9)

Characteristics

p valuea,b

p valuea,b

Age, years

Sex, n (%)
0.1288

0.0005

Duration of CLL from diagnosis to registry enrollment, years
Median

1.4

1.8

Range

0–29

0–32

Median

1.4

1.8

Range

0–29

0–32

0.2912

7.0

7.2

0–32

0–30

1.4

2.3

0–32

0–20

0.7074

Time from diagnosis to first LOT, years
0.2593

0.0139

Race, n (%)c,d
White

561 (92.3)

237 (92.9)

Black

40 (6.6)

16 (6.3)

0.7211

352 (90.0)

183 (96.3)

37 (9.5)

5 (2.6)

American Indian/Alaskan native

0

0

1 (0.3)

0

Asian

3 (0.5)

0

1 (0.3)

0

Other

4 (0.7)

2 (0.8)

0

2 (1.1)

0.0076

Geographic region, n (%)c,d
Northeast

75 (12.0)

37 (14.3)

Midwest

207 (33.2)

70 (27.1)

0.2029

58 (14.3)

37 (19.0)

137 (33.7)

45 (23.1)

South

249 (40.0)

103 (39.9)

162 (39.8)

77 (39.5)

West

92 (14.8)

48 (18.6)

50 (12.3)

36 (18.5)

74 (11.7)

12 (4.6)

57 (13.9)

12 (6.1)

Institution type, n (%)
Academic
Community

545 (86.5)

242 (93.4)

343 (83.9)

181 (92.3)

Government

11 (1.7)

5 (1.9)

9 (2.2)

3 (1.5)

283 (44.9)

229 (88.4)

227 (55.5)

175 (89.3)

Insurance, n (%)e
Medicare
Medicaid

28 (4.4)

14 (5.4)

16 (3.9)

7 (3.6)

Supplemental coverage

86 (13.7)

92 (35.5)

81 (19.8)

67 (34.2)

Private coverage

357 (56.7)

46 (17.8)

189 (46.2)

35 (17.9)

HMO

88 (14.0)

16 (6.2)

56 (13.7)

13 (6.6)

PPO

206 (32.7)

26 (10.0)

103 (25.2)

14 (7.1)

Other

64 (10.2)

4 (1.5)

33 (8.1)

8 (4.1)

Military

10 (1.6)

5 (1.9)

5 (1.2)

6 (3.1)

Self-pay

13 (2.1)

0

6 (1.5)

0

Other Insurance

10 (1.6)

3 (1.2)

8 (2.0)

3 (1.5)

Not specified

15 (2.4)

5 (1.9)

19 (4.6)

2 (1.0)

0.016
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Table 1 Demographics and characteristics of patients at enrollment to therapy (Continued)
ECOG score and status, n (%)c,d
0 - Fully active

276 (57.4)

70 (33.7)

138 (46.8)

42 (30.7)

1 - Restricted in strenuous activity only

180 (37.4)

116 (55.8)

<0.001

138 (46.8)

79 (57.7)

2 - Ambulatory, but unable to work

22 (4.6)

19 (9.1)

17 (5.8)

14 (10.2)

3 - Capable of only limited self-care

2 (0.4)

3 (1.4)

2 (0.7)

2 (1.5)

4 - Completely disabled

1 (0.2)

0

0

0

0.0105

Rai staging system score, n (%)c,d
Stage 0

112 (23.7)

60 (28.4)

Stage I

143 (30.2)

48 (22.7)

0.0219

63 (25.2)

46 (32.6)

58 (23.2)

39 (27.7)

Stage II

83 (17.5)

25 (11.8)

43 (17.2)

16 (11.3)

Stage III

71 (15.0)

36 (17.1)

44 (17.6)

24 (17.0)

Stage IV

64 (13.5)

42 (19.9)

42 (16.8)

16 (11.3)

397 (63.0)

183 (71.8)

264 (65.0)

126 (64.3)

Constitutional symptoms, n (%)
f

0.0192

Fatigue

328 (82.6)

152 (83.1)

212 (80.3)

114 (90.5)

Fever

44 (11.1)

16 (8.7)

22 (8.3)

5 (4.0)

Night sweats

164 (41.3)

62 (33.9)

85 (32.2)

27 (21.4)

Other

69 (17.4)

44 (24.0)

54 (20.5)

25 (19.8)

Weight loss

97 (24.4)

60 (32.8)

71 (26.9)

37 (29.4)

Yes

254 (40.3)

93 (35.9)

148 (36.2)

46 (23.5)

Abnormalities foundf

110 (43.3)

48 (51.6)

81 (54.7)

23 (50.0)

del(11q)

24 (9.4)

12 (12.9)

18 (12.2)

5 (10.9)

del(13q)

36 (14.2)

11 (11.8)

23 (15.5)

7 (15.2)

Trisomy 12

41 (16.1)

16 (17.2)

30 (20.3)

8 (17.4)

del(17p)

13 (5.1)

6 (6.5)

12 (8.1)

3 (6.5)

Other

35 (13.8)

18 (19.4)

36 (24.3)

10 (21.7)

0.1728

0.977

Metaphase cytogenetic analysis, n (%)e

FISH analysis, n (%)e
Yes

377 (59.8)

136 (52.5)

157 (38.4)

67 (34.2)

281 (74.5)

99 (72.8)

116 (73.9)

44 (65.7)

del(11q)

64 (17.0)

26 (19.1)

31 (19.7)

14 (20.9)

del(13q)

179 (47.5)

59 (43.4)

69 (43.9)

30 (44.8)

Trisomy 12

74 (19.6)

31 (22.8)

38 (24.2)

10 (14.9)

del(17p)

33 (8.8)

18 (13.2)

28 (17.8)

9 (13.4)

Other

24 (6.4)

14 (10.3)

11 (7.0)

6 (9.0)

263

106

179

79

Abnormalities foundf

ALC (×109/L)
9

a

Mean (×10 /L)

68.5

58.4

52.7

54.2

SD

75.7

62.9

64.5

51.9

Median (×109/L)

46.1

34.6

25.6

40.1

Range (×109/L)

0–564.0

1.3–275.4

0.1–306.0

0.8–271.1

p values (bold text) calculated using a Chi-square test. p values of interest are shown. Data are missing. Rounding of numbers may cause totals to be =, <, or >
100%. eMore than one answer permitted. fPercentages calculated based on the number of patients tested
ALC absolute lymphocyte count, CLL chronic lymphocytic leukemia, ECOG Eastern Cooperative Oncology Group, FISH fluorescence in-situ hybridization, HMO health
maintenance organization, LOT1 first line of therapy, LOT ≥ 2 second line of therapy or greater, PPO preferred provider organization, SD standard deviation
b

this approach. In multivariable analyses, significant predictors
of death due to CLL or infection included choice of
enrollment therapy, CCI score, time from diagnosis, anemia

c

d

at enrollment, sex, and race. However, validation of these
models did not provide consistent results primarily due to
the small size of the validation datasets. Therefore, a decision
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Table 2 Type of therapy by age group (most frequently used regimens)
Regimen

< 75 years
Rituximab monotherapy, n (%)
Combinations with rituximab, n (%)

LOT ≥ 2 (n = 605)

LOT1 (n = 889)
≥ 75 years

p valuea,b

< 75 years

≥ 75 years

p valuea,b

(n = 630)

(n = 259)

(n = 409)

(n = 196)

54 (8.6)

50 (19.3)

<0.0001

52 (12.7)

30 (15.3)

0.3834

482 (76.5)

139 (53.7)

<0.0001

243 (59.4)

90 (45.92)

0.0018

Bendamustine/rituximab

126 (20.0)

61 (23.6)

0.2377

125 (30.6)

43 (21.9)

0.0267

Bendamustine/dexamethasone/rituximab

5 (0.8)

4 (1.5)

5 (1.2)

0

Chlorambucil/rituximab

0

4 (1.5)

0

0

Cyclophosphamide/rituximab

0

0

0

3 (1.5)

Cyclophosphamide/fludarabine/dexamethasone/rituximab

8 (1.3)

0

0

0

Cyclophosphamide/lenalidomide/rituximab

0

0

4 (1.0)

0

Cyclophosphamide/pentostatin/rituximab

21 (3.3)

3 (1.2)

13 (3.2)

0

Cyclophosphamide/vincristine/prednisone/rituximab

14 (2.2)

9 (3.5)

8 (2.0)

6 (3.1)

Fludarabine/cyclophosphamide/rituximab

212 (33.7)

18 (6.9)

41 (10.0)

11 (5.6)

<0.0001

Fludarabine/rituximab

33 (5.2)

22 (8.5)

14 (3.4)

11 (5.6)

Lenalidomide/rituximab

10 (1.6)

0

0

0

Prednisone/rituximab

0

4 (1.5)

0

3 (1.5)

Investigational product/rituximab

14 (2.2)

0

0

0

65 (10.3)

52 (20.1)

45 (11.0)

50 (25.5)

23 (3.7)

8 (3.1)

24 (5.9)

21 (10.7)

Chlorambucil

18 (2.9)

22 (8.5)

6 (1.5)

12 (6.1)

Chlorambucil/prednisone

0

12 (4.6)

0

3 (1.5)

Cyclophosphamide

0

4 (1.5)

0

0

Cyclophosphamide/fludarabine

11 (1.7)

0

0

2 (1.0)

Cyclophosphamide/vincristine/prednisone

0

0

5 (1.2)

0

Fludarabine

9 (1.4)

0

5 (1.2)

10 (5.1)

Other, n (%)

14 (2.2)

16 (6.2)

46 (11.3)

18 (9.2)

Alemtuzumab

0

0

14 (3.4)

6 (3.1)

Lenalidomide

0

4 (1.5)

0

0

Ofatumumab

0

0

17 (4.2)

8 (4.1)

Investigational product

6 (1.0)

7 (2.7)

13 (3.2)

4 (2.0)

Chemotherapy alone, n (%)
Bendamustine

<0.0001

0.0030

0.0700

<0.0001

0.4400

p values (bold text) calculated using a Chi-square test. bp value shown for large patient groups only
LOT1 first line of therapy, LOT ≥ 2 second line of therapy or greater
a

was made to identify independent predictors of death among
the covariates that were part of at least one multivariable
model. These covariates were used in the final model.
Three predictors were identified: time from diagnosis to
first treatment, enrollment therapy other than BR, and
anemia. Based on the relative magnitude of effect, each
predictor was weighted and assigned a score [19]. Time
from diagnosis to treatment < 3 months and therapy other
than BR were assigned a score of 2; anemia at enrollment
was assigned a score of 1. Patients were classified into risk
groups: lower-risk (score ≤ 4) and higher-risk (score = 5).
When stratified by risk, mortality due to CLL or infection
was 10.3% in the lower-risk group (n = 145) compared with
30.6% in the higher-risk group (n = 36) (Chi-square

p = 0.0002). This prognostic model was validated in a
multivariate analysis of all patients with a grouping variable
and interaction terms for each of the significant covariates.
Serious adverse events

Serious adverse events (SAEs) of any grade were more
common in patients ≥ 75 years than patients < 75 years
in LOT1 (56.0 vs. 39.4%) and LOT ≥ 2 (68.4 vs. 61.9%)
(Additional file 4: Table S3). Grade ≥ 3 SAEs were more
common in elderly CLL patients in LOT1 (51.4 vs.
34.8%) (Additional file 5: Table S4). The most frequent
grade ≥ 3 SAE, pneumonia, was more common in elderly
CLL patients in LOT1 (9.7%) than in patients < 75 years
(4.0%); however, in LOT ≥ 2 rates of grade ≥ 3 pneumonia
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n = 630
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2.1 2.4

0.0
1.1

10.0

3.5

5.8
3.9
5.8
68.0
86.8

c

d

n = 409
2.2

n = 196

2.6

1.0

1.0

17.6
25.5
1.0

42.3

2.2

9.0
2.0

62.3

2.6

2.4
13.8

2.2

5.6

4.6

Cardiac event

Richter's transformation
(Large B-cell lymphoma)

Other

Vascular event

Second primary malignancy

Unknown

CLL progression

Infection

Alive

Fig. 1 Cause of death among patients enrolled on the registry. Cause of death is shown for a patients aged < 75 years in LOT1; b patients
aged ≥ 75 years in LOT1; c patients aged < 75 years in LOT ≥ 2; d patients aged ≥ 75 years in LOT ≥ 2. Rounding of values may cause totals to
be equal, >, or < 100%. CLL chronic lymphocytic leukemia, LOT1 first line of therapy, LOT ≥ 2 second line of therapy or greater

were similar in both groups (12.8 vs. 13.7%, respectively).
In LOT ≥ 2, febrile neutropenia, thrombocytopenia, and
pyrexia were more common in patients < 75 years
(Additional file 4: Table S3 and Additional file 5: Table S4).

Discussion
While inferior OS is expected in elderly CLL patients, our
analysis of elderly CLL patients treated in a ‘real-world’ setting showed that these patients are more likely to experience
CLL- or infection-related deaths. To our knowledge, this has
not been reported previously. We developed a prognostic
score specifically for this vulnerable patient population,
which classified the elderly CLL cohort into high- and lowrisk groups with statistical variation in CLL-related mortality.
As the US population ages, identifying optimal therapeutic strategies for the elderly is a critical unmet medical
need as few prospective trials have targeted this patient
population. Moreover, elderly patients enrolled in clinical
trials might not represent the general elderly population

treated in the community. While geriatric assessments
should be used to provide an objective and comparable
measure of elderly status [20], most studies define elderly
patients based solely on an age cut-off. As the median age
at diagnosis is 72 years, we selected ≥ 75 years of age as the
cut-off for this analysis. While there are limitations to
selecting an age cut-off, we postulated that a cut-off above
the median age at diagnosis would be clinically meaningful.
In addition, published prospective data on outcomes for
patients who are ≥ 75 years of age are limited [21, 22].
Elderly CLL patients were more often treated with rituximab monotherapy than their younger counterparts who
were more likely to receive chemoimmunotherapy [22].
However, the fact that 20% of elderly CLL patients did not
receive an anti-CD20 monoclonal antibody is striking, given
that all patients were treated after 2010. Even in the younger
cohort, we observed that 10% of patients did not receive any
anti-CD20 antibodies. To better understand this variation,
we assessed whether patterns of care differed based on
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113 (58%)

Censored Median (95% Cl)
255 (62%)
–
83 (42%) 31.0 (23.0, 38.0)

Fig. 2 Overall survival in elderly CLL patients vs. younger patients. Kaplan–Meier curves of OS for patients in a LOT1 and b LOT ≥ 2 stratified by age.
Percentages are rounded to the nearest whole number. CI confidence interval, LOT1 first line of therapy, LOT ≥ 2 second line of therapy or greater,
OS overall survival

health insurance coverage or geographic location of the
treating institution. Elderly CLL patients were less likely to
receive rituximab-based therapies than younger patients,
regardless of insurance provider. However, patients residing in the South were more likely to receive anti-CD20
therapy compared with patients living on the West coast. A
comparable observation was reported in a study of follicular
lymphoma patients in the West of the USA who were less
likely to receive rituximab-based maintenance therapy [23].
This may reflect differences in the treating institution and/
or setting. Rituximab use has increased in hospitals while

declining in clinics, which could account for the imbalance in treatment between geographic locations [24].
These data suggest that real-world findings differ from
clinical trial observations.
Regardless of LOT, responses appeared lower in elderly
CLL patients. Although responses were assessed by treating
physicians and were not centrally reviewed, CR in the
younger patients at LOT1 (42.3%) was comparable to the response (44%) reported for treatment-naïve patients in the
CLL-8 trial of rituximab plus fludarabine/cyclophosphamide
[6]. Only 25.9% of elderly CLL patients achieved a CR in
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Fig. 3 Cumulative incidence of deaths in elderly CLL patients vs. younger patients. CIF of CLL-related deaths stratified by age in a LOT1 and b
LOT ≥ 2, and CLL- or infection-related deaths stratified by age in c LOT1 and d LOT ≥ 2, demonstrating increased mortality in elderly CLL patients
(red line). Horizontal dashed line shows median survival in patients ≥ 75 years. CI confidence interval, CIF cumulative incidence functions, CLL chronic
lymphocytic leukemia, LOT1 first line of therapy, LOT ≥ 2 second line of therapy or greater

LOT1. Given the association between survival and the depth
of remission [25], this finding is critical and might contribute
to the inferior outcomes noted in our elderly cohort.
Despite the typically indolent nature of CLL, we observed
critical outcome differences at a median follow-up of
32.6 months. OS was inferior in elderly CLL patients in any
LOT group. Given the predictably inferior OS in the elderly
due to competing co-morbidities and deaths from other
causes, we compared CLL-related deaths between both
groups in LOT1 and LOT ≥ 2. Only 5% of patients < 75 years
in LOT1 experienced CLL-specific deaths while 13% of elderly CLL patients died from CLL alone. This difference was
statistically significant (p = 0.0005). A similar observation was
noted in LOT ≥ 2 (31% for ≥ 75 years vs. 22% for < 75 years;
p = 0.0277). Since infections are a major cause of CLL-related
deaths, we evaluated the differences in deaths due to CLL or
infection in both LOT groups. The difference remained
significant (p < 0.0001 in LOT1; p = 0.0014 in LOT ≥ 2).
We subsequently studied prognostic indicators for CLL- or
infection-related deaths in elderly CLL patients. We identified
three factors that were significant in a multivariable analysis:
time from diagnosis to therapy initiation of < 3 months,
enrollment therapy other than BR, and anemia. While a time
from diagnosis to therapy of < 3 months may suggest patients
had more aggressive disease, this is not necessarily related to
disease staging. Indeed, the majority of patients in each LOT
and age group had Rai stage 0–2. Rai stage did also not differ
significantly between younger and older patients. The

prognostic score was used to classify elderly CLL patients
according to high- or low-risk of CLL-related death (30.6
vs. 10.3%, respectively; p = 0.0002). Contrary to the prognostic models published by Pflug et al. [26], and The International Prognostic Index for patients with CLL (CLL-IPI)
working group [27] in which all patients were included
regardless of age, our score was specifically designed for
elderly CLL patients. Notably, Pflug et al. [26] and the
CLL-IPI working group [27] identified older age as an independent factor negatively impacting survival. Our model
is also specific to patients receiving therapy as patients
under observation were not enrolled to the registry.
Several limitations inherent in any registry-based observational study were encountered during our study. These
include the non-random allocation of patients to specific
interventions, the assessment of outcomes by non-blinded
individuals, and the greater potential for missing data [28].
In the Connect CLL registry, responses were not centrally
assessed and indications to treat were based on the treating physician’s judgment. Comprehensive molecular and
cytogenetic evaluation was missing for some patients. Our
analysis also has limitations that are specific to the Connect CLL registry. Only patients requiring therapy were
enrolled in the registry. Patients who died without starting
therapy were excluded. The registry predates the introduction of BCR-targeted therapies; therefore, the patients in
this registry were not treated with these novel agents. As
with any registry, patients were treated with a number of
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different therapies. The small size of the cohort and the
inclusion of only 181 patients in the prognostic model
may also be limiting factors. However, despite the small
sample size we believe that these results are meaningful as
they relate specifically to elderly patients. Importantly,
these data also represent the largest US population of CLL
patients treated outside of interventional clinical trials in
the chemoimmunotherapy era.
Our finding of increased mortality related to elderly
CLL patients highlights the urgent need for therapies
tailored to this population and underscores the need to
refine CLL treatment for the elderly as current therapies
and strategies appear suboptimal. This might reflect a
limited enrollment of elderly patients into clinical trials
and highlight a flaw in the assumption that effective regimens in younger patients will be effective in elderly patients. As new BCR-targeted agents are increasingly
used, their role in elderly CLL patient treatment will
require critical analysis to balance efficacy with toxicity.
Our data on CLL- and infection-related mortality using
traditional therapies are a benchmark against which novel
therapies can be measured. Finally, the proposed prognostic
score, while requiring validation in patients treated with
BCR-targeted therapies, could be used to stratify elderly
CLL patients on their enrollment into future clinical trials.

Conclusion
These data represent the real-world experiences of a large
population of CLL patients treated across the USA. Within
the limitations of an observational registry we have shown
that elderly CLL patients have inferior outcomes with a cumulative increased risk of death from CLL regardless of
LOT. Recent improvements in survival for younger patients
with CLL have still to be achieved in elderly CLL patients.
While elderly people have increased mortality versus younger people regardless of CLL status, it will be important to
identify new therapies that can improve the outcomes for
elderly CLL patients, similar to the advances seen in younger
CLL patients. This unique prognostic model for patients ≥ 75 years could identify those patients who
would benefit from early treatment or treatment with
novel therapies.
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